NIAID issues BAA on infectious disease platforms
By supporting the development of integrated clinical sample-to-answer multiplex diagnostic platforms for infectious diseases, NIAID scientists may be able to improve diagnostic testing capabilities for Francisella tularensis, Yersinia pestis, Bacillus anthracis and other bioterror threats, Global Biodefense reports.
The platforms may consist of a single operating unit able to accept a clinical sample or a cartridge and cartridge-operating unit. By the end of the performance period, the integrated clinical sample-to-answer multiplex diagnostic platform must be able to generate actionable diagnostic results within two hours, be used in a primary healthcare setting or in low resource settings and detect specified pathogens from a blood sample without a blood culture step.
Respondents may also propose tests to detect medically important pathogens in other types of clinical samples, including feces, urine, sputum, saliva and other types of samples. The NIAID also seeks to obtain information regarding antimicrobial sensitivity or the resistance of the pathogens.
The NIAID estimates that the average total cost of three contracts for the project is $6 million. The response deadline for the BAA is August 4, Global Biodefense reports.